Beyond PDL1: OBT has recently discovered a novel T cell modulatory axis, OX001R/L, which is involved in cancer immune escape independent of the PD1/PDL1 axis. "
PRESS RELEASES
2021
2020
Date |
Title |
Details |
14 Oct 2020 |
Boehringer Ingelheim and Oxford BioTherapeutics Expand Collaboration to Discover Novel Selective Tumor Targets as First Bispecific Antibody Advanced into the Clinic |
View here |
09 Jan 2020 |
Oxford BioTherapeutics Initiates Dose-Escalation Portion of U.S. Phase I Clinical Trial for OBT076 in Patients with Advanced Solid Tumors |
View here |
2019
Date |
Title |
Details |
25 Jun 2019 |
Oxford BioTherapeutics Announces Receipt of a Milestone Payment as Boehringer Ingelheim Advances an Oncology Drug Candidate |
View here |
2018
Date |
Title |
Details |
21 Dec 2018 |
Oxford BioTherapeutics Receives US FDA IND Clearance for OBT076: An Experimental First in Class ADC Medicine for High Risk Her2 Negative Breast Cancer, Gastric, Lung, Bladder and Ovarian Cancer Patients - US Phase I Clinical Trial to be Initiated |
View here |
11 Dec 2018 |
Oxford BioTherapeutics Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Five Bispecific Antibody Programs for up to $450 Million |
View here |
01 Mar 2018 |
Oxford BioTherapeutics Appoints Chief Medical Officer, Abderrahim Fandi |
View here |
2017
Date |
Title |
Details |
12 Sept 2017 |
Oncology Alliance between Menarini & Oxford BioTherapeutics Progresses Second Candidate MEN1309 into the Clinic, an Antibody Drug Conjugate for the Treatment of Solid Tumors and NHL |
View here |
13 Jun 2017 |
Oxford BioTherapeutics Appoints Senior Clinical Biotech Executive as Non-Executive Director |
View here |
09 Feb 2017 |
Oxford BioTherapeutics Strengthens Board of Directors with Appointment of Two Biotech Veterans |
View here |
26 Jan 2017 |
Oxford Finance Provides $10 Million Senior Debt Facility to Oxford BioTherapeutics |
2016
2015
Date |
Title |
Details |
08 Oct 2015 |
Oxford BioTherapeutics Appoints Shawn Tomasello to its Board of Directors |
View here |
30 Jul 2015 |
Oxford BioTherapeutics Receives $10 Million Capital Term Loan from Silicon Valley Bank |
View here |
23 Feb 2015 |
Oxford BioTherapeutics to Present at 35th Cowen and Company Annual Health Care Conference in Boston |
View here |
14 Jan 2015 |
Oxford BioTherapeutics Grants an Exclusive License to Boehringer Ingelheim for Development and Commercialization of Antibody Products to an Oncology Target |
View here |
2014
Date |
Title |
Details |
25 Nov 2014 |
$1 Billion Oncology Alliance between Menarini Group & Oxford BioTherapeutics initiates First-in-Human Study of Enhanced Antibody for Treatment of Acute Myeloid Leukaemia |
View here |
02 Oct 2014 |
Oxford BioTherapeutics and Berlin-Chemie/Menarini Group Progress Antibody-Drug Conjugate as Second Clinical Development Candidate in $1 Billion Oncology Investment Alliance |
View here |
07 May 2014 |
Oxford BioTherapeutics Takes Exclusive Rights to Use Amgen Xenomouse® Antibodies and ImmunoGen Technology to Develop Novel Antibody-Drug Conjugate for HER2-Negative Breast Cancer |
View here |
2001 - 2013
Date |
Title |
Details |
09 Dec 2013 |
Oxford BioTherapeutics and Menarini Progress Enhanced Antibody for Acute Myeloid Leukemia as First Clinical Development Candidate in $1 Billion Oncology Investment Alliance |
View here |
29 Apr 2013 |
Oxford BioTherapeutics and Boehringer Ingelheim Enter Collaboration to Discover Novel Antibody Targets in Cancer |
View here |
29 Oct 2012 |
Menarini Group and Oxford BioTherapeutics Collaborate for Development and Manufacture of Novel Antibody-based cancer Drugs |
View here |
13 Sept 2011 |
Seattle Genetics and Oxford BioTherapeutics to Collaborate on Antibody-Drug Conjugates for Cancer |
View here |
07 Sept 2011 |
CMC Biologics Licenses its CHEF1® Expression System to Oxford BioTherapeutics |
View here |
02 Sept 2011 |
Oxford BioTherapeutics Licenses Lonza′s GS Gene Expression System™ |
View here |
06 Apr 2011 |
Oxford BioTherapeutics Licenses BioWa′s POTELLIGENT® Technology for the Research and of its Therapeutic Antibodies in Cancer |
View here |
25 Jan 2011 |
Oxford BioTherapeutics Out-Licenses Therapeutic Antibody for the Treatment of Solid Cancers |
|
2001-2010 |
News Archives |
MEDIA
Immunotherapies Expose and Exploit Cancer’s Varied Weaknesses
March 18 2021: “If we could understand why some people reengage their immune system after receiving chemotherapy, while others don’t, we could think about how to combine various therapeutic modalities and in what sequence”, says Christian Rohlff, PhD, CEO of Oxford BioTherapeutics. Read more here about how OBT uses proprietary immuno-oncology technology and antibody-drug conjugates to develop novel therapeutics that can reengage the immune system to destroy cancer cells.
March 18 2021: “If we could understand why some people reengage their immune system after receiving chemotherapy, while others don’t, we could think about how to combine various therapeutic modalities and in what sequence”, says Christian Rohlff, PhD, CEO of Oxford BioTherapeutics. Read more here about how OBT uses proprietary immuno-oncology technology and antibody-drug conjugates to develop novel therapeutics that can reengage the immune system to destroy cancer cells.